Trial Profile
A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Oct 2021
Price :
$35
*
At a glance
- Drugs Felzartamab (Primary) ; Dexamethasone; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MorphoSys
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 08 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Sep 2020.